Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia

Equality Impact Assessment (Guidance development) (MSWord 21 KB)

Register of interests (PDF 135 KB)

Final appraisal determination

Final appraisal determination document (MSWord 51 KB)

Committee papers (PDF 1.96 MB)

Public committee slides (PowerPoint 770 KB)

Draft guidance

Appraisal consultation document (PDF 417 KB)

Committee papers (PDF 10.06 MB)

Public committee slides (PDF 973 KB)

Final scope (PDF 229 KB)

Final matrix (PDF 258 KB)

Draft scope and provisional matrix comments table (post-referral) (PDF 381 KB)

Equality impact assessment (Scoping) (PDF 176 KB)

Draft scope post referral (PDF 323 KB)

Draft matrix post referral (PDF 259 KB)